Ultimovacs ASA announces Two Key Appointments to the Management Team as the Operations Advances
Oslo, October 8, 2021: Ultimovacs ASA today announced two senior appointments to its management team: Orla McCallion as Head of Regulatory Affairs & QA and Anne Worsøe as Head of Investor Relations & Communication, both effective October 1, 2021.
As Head of Regulatory Affairs & QA, Orla McCallion will manage the strategic planning and implementation of regulatory procedures across all Ultimovacs’ development products. Orla brings a wealth of industry knowledge with more than 20 years of experience in the pharmaceutical industry, and is an accomplished scientist and leader within regulatory and clinical development. Orla has regularly interacted with EMA, FDA and other national Regulatory Authorities for scientific advice procedures, submissions for serious conditions, orphan designations and pediatric-related activities and to secure clinical trial approvals. Previously, Orla was Director of Regulatory Affairs at OxThera AB. Orla holds a Ph.D. in Pharmacy from Queen’s University in Belfast.
Orla commented: “I am delighted to join the Ultimovacs team at this exciting time and hope to support the company’s growth as an innovative and leading oncology company.”
As Head of Investor Relations & Communication Anne Worsøe will oversee the communication between Ultimovacs’ management, investors and the broader public. With 20 years of experience within the investment industry, she has extensive knowledge in strategy and business development, internationalization, PR, branding & communication. Anne was the first CEO of the Norwegian Venture Capital & Private Equity Association and Venture Partner at Antler, a global venture capital firm. She spent four years in the USA as Director of Innovation Norway in San Francisco. Anne has served on the Boards of several early-stage companies, venture capital funds, private and public limited companies, and served as an expert jury member at the European Commission’s EIC Accelerator program. Anne holds a Master of Business and Economics from Norwegian Business School.
Anne commented: "I am honored to join Ultimovacs and to work with an extraordinary team of visionary scientists and industry leaders, making a real impact for cancer patients. I am genuinely enthusiastic about the journey ahead for the company. "
“Ultimovacs can attract highly talented people across many disciplines and geographies, and we are very excited to welcome Orla and Anne to our team. Both bring substantial expertise to Ultimovacs at a time when the company is being increasingly recognized as a global leader in therapeutic cancer vaccines,” says CEO Carlos de Sousa.
Ultimovacs’ mission is to and extend and improve the life of patients by enabling the immune system to fight cancer. The Company is developing immune-stimulatory vaccines to treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present in over 80% of cancers in all stages of tumor growth. By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade and increase anti-tumor responses. With a broad Phase II program, Ultimovacs aims to clinically demonstrate UV1’s impact in multiple cancer types in combination with other immunotherapies. Ultimovacs’ second technology approach, based on the proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific peptides and adjuvant in the same molecule and entered Phase I studies in 2021.
For further information, please see www.ultimovacs.com or contact:
Carlosde Sousa, CEO
Phone: +47 908 92507
Anne Worsøe, Head of IR & Communication
Phone: +47 906 86815
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
PubMatic and Semasio Expand Partnership and Deliver Increased Reach for Omnicom Media Group20.10.2021 09:00:00 CEST | Press release
By activating Semasio’s audience segments within PubMatic’s Audience Encore, OMD Netherlands and OMG Germany engaged more consumers compared to DSP activation LONDON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Today, PubMatic, a sell-side platform that delivers superior outcomes for digital advertising, and Semasio, a pioneer in Unified Targeting which seamlessly combines audience and contextual targeting on the buy- and the sell-side, announced an expanded partnership that enables media buyers to increase audience addressability at a user- and page-level. Semasio’s audience and contextual segments can now be activated directly in PubMatic’s sell-side platform (SSP) for rapid, precision targeting. With the prevalence of third-party cookies continuing to decline and consumer privacy paramount, it is important for agencies to re-define audience addressability strategies to optimise reach. A common concern when targeting data segments is the risk of suboptimal reach due to poor cookie match rates.
Nexstim Plc Business and Clinical Update Q3 202120.10.2021 09:00:00 CEST | Press release
Press release,Helsinki, 20 October 2021 at10:00 AM (EEST) Nexstim Plc Business and Clinical Update Q3 2021 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces the key highlights of the Company’s business and clinical progress during Q3 2021. CEO Mikko Karvinen’sBusiness and Clinical Update I’m very happy to inform that following the strongest first half in the history of the company, our operational business has continued to show positive progress during the third quarter of the year. We have continued to focus on the growth of our Diagnostics Business (NBS) and Therapy Business (NBT®) new system sales in both of our key markets in the United States and Europe. At the same time, we have seen interest in our existing NBS and NBT® System customer base for system upgrades and continued to increase the utilisation rate of our installed base to a record level. This has led into steadily growing recurring revenue levels, which creates stability and a new kind of predictabil
Nexstim Abp:s uppdatering om verksamheten och kliniska framstegen tredje kvartalet 202120.10.2021 09:00:00 CEST | Pressemelding
Pressmeddelande, Helsingfors, 20 oktober 2021 kl. 10.00(EEST) Nexstim Abp:s uppdatering om verksamheten och kliniska framstegen tredje kvartalet 2021 Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) redogör för de viktigaste händelserna i bolagets verksamhet och kliniska framsteg tredje kvartalet 2021. Vd Mikko Karvinens synpunkter på affärsverksamheten och kliniska framstegen Det gläder mig att kunna berätta att bolaget efter det starkaste halvåret i dess historia har haft fortsatt positiv tillväxt inom affärsverksamheten under tredje kvartalet. Vi har fortsatt att satsa på att öka försäljningen av nya system inom diagnostikverksamheten (NBS) och terapiverksamheten (NBT®) på bägge två av våra huvudmarknader, nämligen USA och Europa. Samtidigt har befintliga kunder för NBS och NBT® uppvisat ett intresse för systemuppgraderingar, vilket har bidragit till en rekordhög användningsfrekvens av den installerade basen. Som en följd har de återkommande intäkterna ökat, vilket ger
Yara reports improved returns20.10.2021 08:00:00 CEST | Press release
Oslo, 20 October 2021:Yara delivers improved returns reflectinghigher prices in third quarter.Net income was a negative USD 143 million, compared with a positive USD 340 million a year earlier. The negative net income includesa USD 355 million impairment ofSalitre assetsin line with Yara’sregulatory release dated1 August 2021,and a currency translation loss of USD 148 million. Excluding currency effects and special items, the basic earnings per share was USD 1.33 compared with USD 0.88 per share in third quarter 2020. The main elements of the third-quarter results are: Improved returns reflecting higher prices8.3% ROIC1, up from 7.9% a year earlier40% ammonia curtailment in Europe due to natural gas price spike “Yara delivers solid third quarter results, with EBITDA2 excluding special items up 37%, mainly thanks to improved margins. However, the gas price spike in Europe has led to Yara curtailing around 40% of its European ammonia production,” said Svein Tore Holsether, President and
Kinnevik: Interim report 1 January – 30 September 202120.10.2021 08:00:00 CEST | Press release
”We continue to strengthen and build out our growth portfolio at a rapid pace to maintain the momentum of our strategic transformation, and note the interest of founders and investors to partner with us. This is a significant recognition of our ability to identify the businesses of tomorrow and be their preferred investor as they grow and shape a re-imagined everyday.” Georgi Ganev, CEO of Kinnevik Key Strategic Highlights Betterment raised USD 160m in a funding round to accelerate the record growth the company has delivered year-to-date across its B2C and B2B offering, leading to a significant uplift in valuation Cityblock raised additional capital to extend its reach and battle health inequities for a fast-growing member population, at a valuation twice as high as the round in March this yearBabylon reaffirmed its 2021 and 2022 growth guidance and secured USD 200m in sustainability-linked financing as it nears completion of its SPAC merger transaction We strengthened our Growth Portf
ING to offer compensation to Dutch retail customers with certain consumer credit products20.10.2021 08:00:00 CEST | Press release
ING to offer compensation to Dutch retail customers with certain consumer credit products ING announced today to offer a compensation to our Dutch retail customers with certain revolving consumer loans where the variable interest rate did not sufficiently follow market rates. With this step, ING reacts to a number of rulings by the Dutch Institute for Financial Disputes (Kifid) regarding similar products at other banks. We have investigated the relevance of these rulings for our floating-rate credit products in the Netherlands. This is expected to concern approximately 10% of the contracts for these products. The Dutch Consumers’ Association (Consumentenbond) has reacted positively on ING’s intention and is prepared to further discuss the execution and details of the scheme, which is expected to be completed before the end of 2022. ING will book a provision of €180 million in its third quarter 2021 results for the compensation and costs of executing the scheme. More details on the comp
Yara leverer økt avkastning20.10.2021 08:00:00 CEST | Pressemelding
Oslo, 20. oktober 2021:Yara rapporterer økt avkastning i tredje kvartal som følge av høyere priser,Nettoresultatvar negativt USD 143 millionersammenlignet med positivt USD 340 millioner ett år tidligere.Det negative nettoresultatet inkluderer en USD 355 millioner nedskrivning av Salitre-prosjektet med referanse til Yaras børsmelding 1. august 2021, og et valutatap på USD 148 millioner. Nettoresultat eksklusive valutaeffekter og spesielle poster, var USD 1,33 per aksje sammenlignet med USD 0,88 for tredje kvartal 2020. Hovedelementene i resultatet for tredje kvartal er: Økt avkastning som følge av høyere priser8,3 % ROIC1, opp fra 7,9% ett år tidligere40% midlertidig kutt i amoniakkproduksjon i Europa som følge av høy gasspris «Yara leverer et solid resultat for tredje kvartal, med EBITDA1 eksklusive spesielle poster opp 37%, hovedsakelig som følge av økte marginer. Imidlertid har den høye gassprisen i Europa ført til at Yara har midlertidig kuttet ca 40% av sin europeiske ammoniakkprod